乳腺癌病人使用氨磷汀导致一过性红斑1例分析  

Analysis of a case of transient erythema caused by amifostine in a breast cancer patient

作　　者：邹杨颖 ZOU Yangying(Author Affiliation:Department of Pharmacy,Jixi Ji Mine Hospital,Jixi,Heilongjiang 158100,China)

机构地区：[1]鸡西鸡矿医院药学部,黑龙江鸡西158100

出　　处：《安徽医药》2025年第1期210-212,共3页Anhui Medical and Pharmaceutical Journal

摘　　要：目的分析注射用氨磷汀致一过性红斑的不良反应的发生特点、风险因素及处置,为临床安全用药提供参考。方法报道1例分别于2023年3月28日及4月13日鸡西鸡矿医院使用氨磷汀致一过性红斑的不良反应,并检索国内外公开发表的氨磷汀致皮肤不良反应的个案文献,提取不良反应的临床特征、处置措施及预后等信息进行总结。结果氨磷汀引起的皮肤反应罕见,仅收集到5篇氨磷汀致皮肤不良反应的相关文献全部为国外病例。该例病人出现的一过性红斑与检索文献中红斑的描述不全相似,结合检索文献综合分析,该例皮肤不良反应不排除与氨磷汀成分过敏,或对氨磷汀注射剂中相关辅料过敏,或与细胞毒性T细胞介导的发病机制相关。结论临床使用氨磷汀时,需询问病人是否有氨磷汀或甘露醇等相关药物过敏史、是否既往有自身免疫性疾病史,建议在每次给药氨磷汀前进行皮肤评估,可以留意C反应蛋白相关指标以做出相关的用药参考,出现皮肤相关反应,需立即中断药物,可以使用外用药物及系统用药对症改善症状,以确保用药安全性。Objective To analyze the occurrence characteristics,risk factors,and management of adverse reaction of transient erythema caused by injectable amifostine,and to provide references for clinical safe medication.Methods A case of transient erythema caused by amifostine was reported in Jixi Ji Mine Hospital from March 28 and April 13,2023 respectively,and literature of skin adverse reactions caused by amifostine published at home and abroad,and the clinical characteristics,management measures and prognosis of adverse reactions were extracted and summarized.Results Skin reactions caused by amifostine were rare,only five literatures about skin adverse reactions caused by amifostine were collected,all of which were foreign cases.The transient erythema in this patient was not completely similar to the description of erythema in the literatures.Combined with the comprehensive analysis of literature retrieval,the skin adverse reaction in this case did not exclude allergy to the components of amifostine,allergy to the related excipients in amifostine for injection,or related to a cytotoxic T-cell mediated pathogenesis.Conclusions When using amifostine in clinical,it is necessary to ask the patient whether he has allergic history of amifostine or mannitol and other related drugs,and whether he has a history of autoimmune diseases.It is recommended to conduct a skin assessment before each administration of amifostine,and pay attention to the related indicators of C-reactive protein to make relevant drug reference.If skin related reactions occur,the medication should be discontinued immediately,topical and systemic medications can be used to improve symptoms to ensure medication safety.

关 键 词：氨磷汀 一过性改变 红斑 药品不良反应 关联性 预防及处置 

分 类 号：R969.3[医药卫生—药理学]